Clinical trial • Phase III • Neurology|Endocrinology|Other
Clinical trial in Migraine|Trigeminal nerve disorder
Phase III trial for Migraine|Trigeminal nerve disorder. None/Not specified-controlled. 30 participants.
Overview
- Trial Therapeutic Area
- Neurology|Endocrinology|Other
- Trial Disease
- Migraine|Trigeminal nerve disorder
- Trial Stage
- Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 17-03-2025
- First CTIS Authorization Date
- 02-07-2025
Trial design
None/Not specified-controlled Phase III trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 30
Eligibility
Recruits 30 No vulnerable population selected; trial population = healthy volunteers; no information on consent or assent provided in the record..
- Vulnerable Population
- No vulnerable population selected; trial population = healthy volunteers; no information on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 8
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Netherlands
- Earliest CTIS Part Ii Submission Date
- 03-06-2025
- Latest Decision Or Authorization Date
- 02-07-2025
- Processing Time Days
- 29
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Internal Medicine
- Principal Investigator Name
- Antoinette Maassen van den Brink
- Principal Investigator Email
- a.vanharen-maassenvandenbrink@erasmusmc.nl
- Contact Person Name
- Antoinette Maassen van den Brink
- Contact Person Email
- a.vanharen-maassenvandenbrink@erasmusmc.nl
Sponsor
Primary sponsor
- Full Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.